@entity2267 in XXXX Before and After the Introduction of Conjugate Pneumococcal Vaccines.

@entity1 @entity7646 @entity114 @entity2260 @entity2929 @entity5686 @entity2267 @entity1485 @entity3402
OBJECTIVES: To determine whether serotype distribution and antibiotic resistance of @entity2260 acute @entity2267 (AM) in @entity1 have changed in the post pneumococcal conjugate vaccines (PCVs) era. METHODS: Medical records of pneumococcal AM cases, in a tertiary Pediatric Hospital were reviewed from 1/1999-12/2014. @entity2260 isolates were serotyped using the quellung reaction and tested for antibiotic susceptibility by E-test and for @entity7646 resistance genes by PCR. RESULTS: Among 334 @entity1 with AM, @entity2260 was isolated from 89(26.6%) with median age 22 months (IQR: 12-30m). @entity2260 was recovered from ear fluid (58%), mastoid specimens (35.2%), and blood (6.8%). Resistance to @entity114 , @entity2929 and @entity3402 was 12.4%, 49.4% and 18% respectively. Distribution of pneumococcal serotypes before (1999-2005), after the introduction of PCV7 (2006-2010) and after PCV13 (2011-2014) was found: for the PCV7 serotypes 81%, 25%, 0%, (p<0.0001), for PCV13 additional serotypes 16.3%, 70.8%, 63.6%, (p<0.0001) and for non- @entity1485 serotypes 2.3%, 4.1%, 36.3%, (p=0.0002) respectively. Significant increase was detected for the serotype @entity5686 after PCV7 and this trend was not changed after PCV13 (2.3%, 50%, 50% respectively, p<0.0001). A significant proportion of resistant isolates to @entity114 (54.5%) and @entity2929 (34.8%) were identified as @entity5686 . CONCLUSIONS: After the introduction of PCV7 a significant increase of serotype @entity5686 as well as replacement of PCVs serotypes were identified. After PCV13 the overall proportion of @entity2267 and the incidence of serotype @entity5686 were not significantly declined. A significant proportion of resistant isolates to @entity114 and @entity2929 are attributed to serotype @entity5686 .
